U.S. Generic Lipitor Sales Bring Ranbaxy In From Cold For Daiichi Sankyo

Just short of four years after Daiichi Sankyo bought Ranbaxy Laboratories, the acquisition has begun paying dividends, primarily because it got six months of exclusive U.S. rights to Pfizer’s best-selling cholesterol drug Lipitor (atorvastatin).

Just short of four years after Daiichi Sankyo bought Ranbaxy Laboratories, the acquisition has begun paying dividends, primarily because it got six months of exclusive U.S. rights to Pfizer’s best-selling cholesterol drug Lipitor (atorvastatin). Soon after the drug makers merged, Ranbaxy entered virtual regulatory Siberia at the FDA. The Lipitor generic marked Ranbaxy’s first U.S. approval for one of its drugs produced in India since its isolation. The sales since have helped exonerate Joji Nakayama, president and CEO of Daiichi Sankyo, who said Ranbaxy is critical to the Japanese drug maker’s medium- and long-term growth. (Click here for more

)

Welcome to Scrip

Create an account to read this article

More from India

Glenmark Chief On IGI’s Landmark Trispecific Deal: Strong Data Excited AbbVie

 

Glenmark’s managing director talks about IGI’s billion dollar-plus deal with AbbVie, ISB-2001’s striking data, the BEAT platform, other "exciting" pipeline assets and the "blood, sweat and tears" to get to this stage.

Lupin’s Cimzia Biosimilar Candidate Reflects Strategy To Separate Wheat From Chaff

 
• By 

Lupin's choice of a Cimzia biosimilar candidate and partnering with Zentiva reflect a strategy to sort the wheat from the chaff. Of 118 biologics to lose patent protection between 2025 and 2034 as per IQVIA, it’s going for a biosimilar with a single competitor though there could be other spoilers

Wave of Biopharma Licensing Deals in India: ‘The Model Is Working’

 

From vonoprazan and inclisiran to nirsevimab, big pharma has licensed several products to Indian firms as have other biopharma players. Experts discuss the intricacies of such licensing deals amid signs of more action in store and whether geopolitics could dull partnering with Chinese firms.

Watch This Space: Miltenyi‘s ‘Brain-To-Vein,’ Point-Of-Care CAR-T Efforts In India

 

From a letter of intent with BIRAC sealed at BIO 2025 to supporting Immuneel’s CAR-T efforts and a study for point-of-care manufactured anti-CD19 CAR-T cell therapy, Miltenyi Biotec is moving on multiple fronts in India. The German group also expects to advance its own CAR-T candidates.

More from Focus On Asia

Taiho’s Oral, Mutation-Agnostic DMD Candidate Misses Phase III Endpoint

 
• By 

The oral, twice-daily candidate was expected to control decline in motor function in DMD patients regardless of their gene mutations.

Wave of Biopharma Licensing Deals in India: ‘The Model Is Working’

 

From vonoprazan and inclisiran to nirsevimab, big pharma has licensed several products to Indian firms as have other biopharma players. Experts discuss the intricacies of such licensing deals amid signs of more action in store and whether geopolitics could dull partnering with Chinese firms.

Beyond AI Hype: Tokyo-1’s Real Answer On How To Innovate Pharma R&D

 
• By 

Bringing supercomputing power to bear on large-scale calculations for pharma R&D, Tokyo-based Xeureka explains the practical use of AI to empower innovation beyond the hype.